Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
FDA Approval Alert: The Need-to-Know
Advertisement
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
4
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
5
